Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study

• Published in: BMC cardiovascular disorders 2021-08, Vol.21 (1), p.396-396, Article 396
• Main Authors: Li, Fuhai, Xu, Mengying, Fu, Mingqiang, Cui, Xiaotong, Lian, Zhexun, Xin, Hui, Zhou, Jingmin, Ge, Junbo
• Format: Article
• Language: English
• Subjects: Adult; Aged; Analysis; Biological markers; Biomarkers; Biomarkers - blood; Biomechanics; Blood pressure; Cardiac remodeling; Cardiovascular diseases; Cohort analysis; Congestive heart failure; Diagnosis; Echocardiography; Ejection fraction; Female; Fibrosis; Health aspects; Heart failure; Heart failure with reduced ejection fraction; Heart Failure, Systolic - blood; Heart Failure, Systolic - diagnostic imaging; Heart Failure, Systolic - mortality; Heart Failure, Systolic - physiopathology; Hematocrit; Hemoglobin; Humans; Inflammation; Interleukin 1; Interleukin-1 Receptor-Like 1 Protein - blood; Left ventricular mass index; Magnetic Resonance Imaging; Male; Medical prognosis; Middle Aged; Mortality; Patient Readmission; Patients; Predictive Value of Tests; Prognosis; Progression-Free Survival; Prospective Studies; Risk Assessment; Risk Factors; Septum; Software; Soluble suppression of tumorigenicity 2; Stroke Volume; Time Factors; Tumorigenicity; Variables; Ventricle; Ventricular Function, Left; Ventricular Remodeling
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/s12872-021-02191-3

Inflammation is one of the principal triggering mechanisms for left ventricular fibrosis and remodeling in heart failure, leading to adverse clinical outcomes. Soluble suppression of tumorigenicity 2 (sST2), a member of the interleukin-1 receptor family, is assumed to play a significant role in the fibrotic response to inflammation. Left ventricular mass index (LVMI) is a parameter of the prefibrotic inflammatory phase of heart failure preceding remodeling. The present study aimed to investigate the prognostic value of the sST2/LVMI ratio in heart failure with reduced ejection fraction. This was a prospective cohort study. A total of 45 consecutive patients with heart failure with reduced ejection fraction, treated between September 2015 and December 2016, were enrolled. The sST2/LVMI ratio was measured at baseline. The primary endpoint was a composite of cardiovascular mortality and readmission for heart failure. The prognostic impact of the sST2/LVMI ratio was evaluated using a multivariable Cox proportional hazards regression model. Forty-five patients were enrolled in this study. Their average age was 48 ± 14 years, and approximately 20% of them were men. Patients were followed for 9 months, during which the primary outcome occurred in 15 patients. Kaplan-Meier analysis showed that patients with a high sST2/LVMI ratio (≥ 0.39) had shorter event-free survival than those with intermediate (between 0.39 and 0.24) and low ratios (